Welcome to the CJU website » LOG IN


Molecular targeted therapies for renal cell carcinoma
Dec  2007 (Vol.  14, Issue  61, Pages( 48 - 52)
PMID: 18163945


Text-Size + 

  • New advances in technology to directly target specific molecular events in the proliferation of cancer have led to promising results in renal cell carcinoma. Response rates in excess of 70% and complete responses in advanced (metastatic) renal cell carcinoma have caused a change in the paradigm of treatment from immunotherapy. Toxicities are significant, but manageable and pushing the toxicity to tolerability may increase the response rate.

Current Issue

October 2021, Vol.28 No.5
canadian journal of urology